Waters CORP /DE/ 8-K filings

Waters Corporation announced robust second quarter 2026 financial results, exceeding guidance with strong revenue growth and raising its full-year financial outlook.

Waters Corporation announced first quarter 2026 financial results, exceeding revenue guidance and raising full-year forecasts following the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses.

Augusta SpinCo Corporation, a Waters Corporation subsidiary, successfully completed a $3.5 billion senior notes offering to refinance existing debt.

Waters Corporation finalized its acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, creating a combined entity with significant debt and lower pro forma earnings.

Waters Corporation finalized its Reverse Morris Trust transaction with Becton, Dickinson and Company, integrating BD's Biosciences & Diagnostic Solutions businesses and forming a global life sciences and diagnostics leader.

Waters Corporation announced robust fourth quarter and full-year 2025 financial results, highlighted by double-digit non-GAAP EPS growth and the strategic acquisition of BD Biosciences and Diagnostic Solutions.

Waters Corporation shareholders overwhelmingly approved the issuance of shares for the proposed combination with BD's Biosciences & Diagnostic Solutions business, with the transaction expected to close on February 9, 2026.

Waters Corporation has filed supplemental disclosures to its proxy statement/prospectus for the upcoming merger with BD's Biosciences and Diagnostic Solutions business, addressing shareholder litigation and demand letters.

Waters Corporation presented a robust financial outlook and detailed the strategic acquisition of BD's Biosciences and Diagnostic Solutions business at the J.P. Morgan Healthcare Conference, projecting significant value creation.

Waters Corporation reported strong third-quarter 2025 financial results, exceeding sales and non-GAAP EPS guidance and raising its full-year outlook, driven by robust Pharma segment growth and new product uptake.

Waters Corporation reported strong second-quarter 2025 financial results, exceeding sales and EPS guidance, and raised its full-year outlook.

Waters Corporation has entered into definitive agreements to acquire Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business through a Reverse Morris Trust transaction, creating a new, expanded entity with significant strategic implications.

Waters Corporation and Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business have entered into a definitive agreement to combine in a $17.5 billion Reverse Morris Trust transaction, aiming to create a leading life science and diagnostics company with an expanded market presence and significant synergy potential.

Waters Corporation has successfully amended and restated its credit agreement, replacing its term loan with an expanded revolving credit facility and extending its maturity to May 2030, providing enhanced financial flexibility for general corporate purposes including acquisitions and share repurchases.

Waters Corporation announced that its stockholders re-elected all nominated directors, ratified PricewaterhouseCoopers LLP as its independent auditor, approved executive compensation, and adopted an amended employee stock purchase plan at its annual meeting on May 22, 2025.

Waters Corporation reported strong Q1 2025 results, exceeding expectations with sales of $662 million and raising its full-year sales and EPS guidance.

Waters Corporation reports better-than-expected Q4 and full-year 2024 financial results, driven by strong growth in the pharmaceutical sector and operational excellence, and issues a positive outlook for 2025.

Waters Corporation presented its growth strategy and financial performance at the J.P. Morgan Healthcare Conference, highlighting its strong business model and future opportunities.

Waters Corporation has appointed Heather Knight to the Nominating and Corporate Governance Committee, effective immediately, following her appointment to the Board of Directors earlier in August.

Waters Corporation reported strong third-quarter 2024 results, exceeding sales and earnings guidance, and raised its full-year outlook.

Waters Corporation has appointed Heather Knight to its Board of Directors, increasing its size from nine to ten members, effective August 14, 2024.

Waters Corporation reported second-quarter results that surpassed expectations, driven by strong performance in China and M&A contributions, despite a 4% decline in overall sales.

Waters Corporation has entered into a Master Note Facility Agreement, allowing for the potential issuance of up to $200 million in senior promissory notes.

Waters Corporation held its annual meeting of stockholders on May 23, 2024, where all nominated directors were re-elected and other key proposals were approved.

Waters Corporation's first quarter 2024 sales declined by 7% as reported, but the company maintained its full-year guidance, citing strong operational performance.

Waters Corporation's Q4 2023 sales declined by 4.5% as reported, and 8% organically in constant currency, while full-year sales decreased by 0.5% as reported and 2% organically in constant currency, with margin expansion driven by operational excellence.